MMAI

MMAI (Methyl-MMDA-2 or Methyl-6,7-methylenedioxy-2-aminoindane) is a drug that is a derivative of the aminoindane class. It was developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) with Ki values of 434 nM for serotonin transporter and >100,000 nM for dopamine transporter and norepinephrine transporter.

Etymology

The name MMAI is an acronym that stands for Methyl-6,7-methylenedioxy-2-aminoindane. The name is derived from the chemical structure of the compound, which includes a methyl group (CH3), a methylenedioxy group (O2CH2), and an aminoindane backbone.

Pharmacology

MMAI is a selective serotonin releasing agent, which means it promotes the release of serotonin in the brain. This can lead to various physiological and psychological effects, such as mood enhancement, increased sociability, and potentially hallucinogenic effects. However, unlike other serotonin releasing agents, MMAI does not release dopamine or norepinephrine, which means it does not have the same stimulant or cardiovascular effects as drugs like MDMA or amphetamine.

History

MMAI was first synthesized in the 1990s by a team led by David E. Nichols at Purdue University. The team was investigating the structure-activity relationships of various psychedelic drugs, and MMAI was one of the compounds they developed. Despite its interesting pharmacological profile, MMAI has not been widely studied or used, and its potential therapeutic uses are not well understood.

See also

• MDMA
• Amphetamine
• Serotonin releasing agent
• David E. Nichols

References

MMAI Resources
Latest articles Most recent articles Ongoing trials	Wikipedia